Immunotherapy before and after lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have non-small cell lung cancer (NSCLC) that is stage II to IIIB (meaning the cancer has not spread to distant organs).
- You are healthy enough to undergo lung surgery.
- You have not received prior cancer treatment for this lung cancer.
- You do not have an active autoimmune disease or an infection like hepatitis B, hepatitis C, or HIV.
- You are willing to use effective birth control during the study and for at least 120 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares giving immunotherapy at different times around surgery for stage II-IIIA non-small cell lung cancer. The goal is to find the best time to use this treatment to improve outcomes.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy before surgery in people with Stage III lung cancer that can't be removed at first. The goal is to shrink the tumor so it can be surgically removed.
This study looks at a treatment plan that uses immunotherapy before and after surgery for non-small cell lung cancer. The goal is to see if this approach helps patients do better and to find out which patients benefit most.
This study looks at using immunotherapy before surgery for stage II-III lung cancer. It aims to find markers that predict how well this treatment works, potentially leading to more personalized care.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Hear when a new Stage II-IIIB(N2) Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.